FocusOn Neurology
  • Gastrointestinal Resource Center
  • Highlights from ACG2024 - Focus on Ulcerative Colitis
  • Highlights from ACG2024 - Focus On Fatty Liver Disease
  • Inflammatory Bowel Disease
  • NASH Resource Center
  • Highlights from DDW 2025
  • Highlights from ACG 2025 - Focus on Ulcerative Colitis
  • Highlights from ACG 2025 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Primary Biliary Cholangitis Knowledge Hub
  • C. difficile & Microbiome Therapeutics Knowledge Hub
  • Gastrointestinal Resource Center
  • Highlights from ACG2024 - Focus on Ulcerative Colitis
  • Highlights from ACG2024 - Focus On Fatty Liver Disease
  • Inflammatory Bowel Disease
  • NASH Resource Center
  • Highlights from DDW 2025
  • Highlights from ACG 2025 - Focus on Ulcerative Colitis
  • Highlights from ACG 2025 - Focus on Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Primary Biliary Cholangitis Knowledge Hub
  • C. difficile & Microbiome Therapeutics Knowledge Hub

Advanced Search

Advanced Search

  • Featured:
  • Primary Biliary Cholangitis Knowledge Hub
  • C. difficile & Microbiome Therapeutics Knowledge Hub

Test Your Knowledge

Back to C. difficile & Microbiome Therapeutics Knowledge Hub
  1. What are the most common risk factors for Clostridioides difficile infection (CDI) outside of the hospital setting?
  2. According to current guidelines from the American College of Gastroenterology, which of the following are recommended for the initial treatment of severe Clostridioides difficile infection (CDI)?
    Note: Current guidelines define severe CDI in patients with white blood cell count ≥15,000 cells/mm3 or serum creatinine >15 mg/dL.1
  3. Approximately what percentage of patients will experience an initial recurrence of Clostridioides difficile infection (CDI) after their first treatment?
  4. What are the hypothesized mechanisms underlying the effects of fecal microbiota transplant (FMT, or intestinal microbiota transplant [IMT]) and live biotherapeutic products in patients with inflammatory bowel disease?
  5. What are the perceived benefits of developing cultured live biotherapeutics for the treatment of recurrent Clostridioides difficile infection (CDI)?

References

  1. Kelly, CR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124-1147. doi: 10.14309/ajg.0000000000001278
  2. Montrose JA. Current and future microbiome-based therapies in inflammatory bowel disease. Curr Opin Gastroenterol. 2024;40(4):258-267. doi: 10.1097/MOG.0000000000001027.
  3. Normington C, et al. Clostridioides difficile infections; new treatments and future perspectives. Curr Opin Gastroenterol. 2024; 40(1):7-13. doi: 10.1097/MOG.0000000000000989.
FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2026 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More